• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Orchestra BioMed Holdings Inc.

    2/14/25 4:06:04 PM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $OBIO alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 2)


    Orchestra BioMed Holdings, Inc.

    (Name of Issuer)


    Common Stock, Par Value $0.0001 Per Share

    (Title of Class of Securities)


    68572M106

    (CUSIP Number)


    12/31/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    68572M106


    1Names of Reporting Persons

    Medtronic plc
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    IRELAND
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    5,868,916.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    5,868,916.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,868,916.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    15.4 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  Calculated based on 38,013,526 shares of Common Stock issued and outstanding as of November 7, 2024, as reported in the Issuer's Quarterly Report on Form 10-Q filed November 12, 2024.


    SCHEDULE 13G

    CUSIP No.
    68572M106


    1Names of Reporting Persons

    Covidien Group S.a.r.l.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    LUXEMBOURG
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    5,868,916.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    5,868,916.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,868,916.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    15.4 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  Calculated based on 38,013,526 shares of Common Stock issued and outstanding as of November 7, 2024, as reported in the Issuer's Quarterly Report on Form 10-Q filed November 12, 2024.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Orchestra BioMed Holdings, Inc.
    (b)Address of issuer's principal executive offices:

    150 UNION SQUARE DRIVE, NEW HOPE, PENNSYLVANIA, 18938.
    Item 2. 
    (a)Name of person filing:

    Medtronic plc Covidien Group S.a.r.l.
    (b)Address or principal business office or, if none, residence:

    Medtronic plc: 20 On Hatch, Lower Hatch Street, Dublin 2, Ireland Covidien Group S.a.r.l.: 3b, Bd. Prince Henri, 4th Floor L-1724 Luxembourg
    (c)Citizenship:

    Medtronic plc: Ireland Covidien Group S.a.r.l.: Luxembourg
    (d)Title of class of securities:

    Common Stock, Par Value $0.0001 Per Share
    (e)CUSIP No.:

    68572M106
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See Cover Pages, Items 5 through 11.
    (b)Percent of class:

    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:


     (ii) Shared power to vote or to direct the vote:


     (iii) Sole power to dispose or to direct the disposition of:


     (iv) Shared power to dispose or to direct the disposition of:


    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Medtronic plc
     
    Signature:/s/ Tom Osteraas
    Name/Title:Assistant Secretary and Legal Director
    Date:02/14/2025
     
    Covidien Group S.a.r.l.
     
    Signature:/s/ Salvador Sens
    Name/Title:General Manager
    Date:02/14/2025
    Get the next $OBIO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OBIO

    DatePrice TargetRatingAnalyst
    12/10/2025$15.00Buy
    TD Cowen
    8/20/2025Buy → Neutral
    BTIG Research
    3/20/2025$12.00Buy
    BTIG Research
    1/2/2025$16.00Overweight
    Barclays
    8/22/2024$14.00Buy
    H.C. Wainwright
    7/25/2024$15.00Buy
    B. Riley Securities
    1/19/2024$14.00Buy
    Jefferies
    2/24/2023$15.00Overweight
    Piper Sandler
    More analyst ratings

    $OBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TD Cowen initiated coverage on Orchestra BioMed with a new price target

    TD Cowen initiated coverage of Orchestra BioMed with a rating of Buy and set a new price target of $15.00

    12/10/25 8:29:27 AM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    Orchestra BioMed downgraded by BTIG Research

    BTIG Research downgraded Orchestra BioMed from Buy to Neutral

    8/20/25 8:28:57 AM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    BTIG Research initiated coverage on Orchestra BioMed with a new price target

    BTIG Research initiated coverage of Orchestra BioMed with a rating of Buy and set a new price target of $12.00

    3/20/25 8:00:48 AM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    $OBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Principal Accounting Officer Aiello Joshua

    4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

    2/13/26 5:02:11 PM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    Officer Sherman Darren was granted 397,000 shares, increasing direct ownership by 47% to 1,237,569 units (SEC Form 4)

    4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

    2/13/26 5:01:46 PM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Financial Officer Taylor Andrew Lawrence was granted 181,000 shares, increasing direct ownership by 40% to 632,493 units (SEC Form 4)

    4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

    2/13/26 5:01:15 PM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    $OBIO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences

    NEW HOPE, Pa., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) ("Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced that company management will participate in multiple upcoming institutional investor conferences. Details on the Company's participation appear below: TD Cowen 46th Annual Health Care Conference – March 2-4, 2026 (Boston, MA) Management will participate in a live fireside chat at 9:50am ET on Tuesday, March 3rd and will also host one-on-one meetings with investors. The event will be a

    2/19/26 8:00:00 AM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    NEW HOPE, Pa., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) ("Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, reported today that, on February 12, 2026, the Compensation Committee of the Orchestra BioMed Board of Directors granted stock options to purchase an aggregate of 120,000 shares of the Company's common stock to nine newly hired employees. The awards were granted pursuant to the Orchestra Biomed Holdings, Inc. 2025 New Hire Inducement Plan as an inducement material to each new employee entering employment w

    2/13/26 4:05:00 PM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    Orchestra BioMed to Receive Up to $21 Million in Proceeds from Acquisition of Vivasure by Haemonetics

    $11 million in proceeds expected to be received during 2026, with remainder of expected proceeds to be received in future revenue earnoutsVivasure Medical Limited ("Vivasure") has been a strategic holding of Orchestra BioMed since the Company's formation NEW HOPE, Pa., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that it expects to receive up to $21 million in cash proceeds in connection with the acquisition of Vivasure, an Ireland-based company pioneering next-generation techn

    1/12/26 9:00:00 AM ET
    $HAE
    $OBIO
    Medical/Dental Instruments
    Health Care
    Medicinal Chemicals and Botanical Products

    $OBIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Hochman David P bought $20,350 worth of shares (5,000 units at $4.07), increasing direct ownership by 0.82% to 612,822 units (SEC Form 4)

    4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

    11/17/25 5:00:21 PM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Aryeh Jason bought $2,450 worth of shares (1,000 units at $2.45), increasing direct ownership by 0.93% to 108,482 units (SEC Form 4)

    4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

    9/19/25 6:57:57 PM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Fain Eric S bought $15,034 worth of shares (5,760 units at $2.61) (SEC Form 4)

    4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

    8/25/25 7:04:50 PM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    $OBIO
    SEC Filings

    View All

    SEC Form 8-K filed by Orchestra BioMed Holdings Inc.

    8-K - Orchestra BioMed Holdings, Inc. (0001814114) (Filer)

    2/13/26 5:00:32 PM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form S-8 filed by Orchestra BioMed Holdings Inc.

    S-8 - Orchestra BioMed Holdings, Inc. (0001814114) (Filer)

    2/6/26 4:15:42 PM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form S-8 filed by Orchestra BioMed Holdings Inc.

    S-8 - Orchestra BioMed Holdings, Inc. (0001814114) (Filer)

    2/6/26 4:15:29 PM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    $OBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Orchestra BioMed Holdings Inc.

    SC 13D/A - Orchestra BioMed Holdings, Inc. (0001814114) (Subject)

    8/7/24 5:19:57 PM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form SC 13D/A filed by Orchestra BioMed Holdings Inc.

    SC 13D/A - Orchestra BioMed Holdings, Inc. (0001814114) (Subject)

    8/7/24 5:16:55 PM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form SC 13G/A filed by Orchestra BioMed Holdings Inc.

    SC 13G/A - Orchestra BioMed Holdings, Inc. (0001814114) (Subject)

    7/17/24 4:32:50 PM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    $OBIO
    Leadership Updates

    Live Leadership Updates

    View All

    Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update

    NEW HOPE, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its full year 2024 financial results and provided a fourth quarter business update. "We remain highly focused on execution of the BACKBEAT global pivotal study, which we believe has the potential to deliver landmark results that can establish AVIM therapy as a new standard of care for the treatment of uncontrolled hypertension in patients already indicated for a pacemaker. We also believe it can lay the foundation for

    3/31/25 4:21:30 PM ET
    $MDT
    $OBIO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medicinal Chemicals and Botanical Products

    Orchestra BioMed Appoints Vivek Reddy, M.D. as Executive Chairman of the BACKBEAT Study Steering Committee and Chairman of Bioelectronic Therapies Scientific Advisory Board

    The BACKBEAT global pivotal study is currently enrolling patients to evaluate the efficacy and safety of atrioventricular interval modulation ("AVIM") therapy for patients who have uncontrolled hypertension and a pacemaker indicationA globally recognized thought leader and innovator in cardiovascular technologies, including electrophysiology and cardiac rhythm management, Dr. Reddy currently serves as the Director of Cardiac Arrhythmia Services at The Mount Sinai Fuster Heart Hospital, the Director of Electrophysiology for the Mount Sinai Health System, and the Leona M. and Harry B. Helmsley Charitable Trust Professor of Medicine in Cardiac Electrophysiology at the Icahn School of Medicine a

    2/18/25 8:00:00 AM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    Orchestra BioMed Announces Appointment of Former Medtronic SVP of Corporate Development Christopher Cleary to Board of Directors

    Medical device industry veteran brings over three decades of expertise in M&A, as well as structured research and development ("R&D") collaborations aligned with Orchestra BioMed's partnership-enabled business model Mr. Cleary previously served as Senior Vice President ("SVP") of Corporate Development at Medtronic plc (NYSE:MDT) ("Medtronic"), where he played a key role in establishing the strategic collaboration between Orchestra BioMed and Medtronic for atrioventricular interval modulation ("AVIM") therapy in hypertension with increased cardiovascular riskEric A. Rose, M.D. to transition from Board Member to Board Member Emeritus and Strategic Advisor, continuing to provide invaluable expe

    2/5/25 8:00:00 AM ET
    $MDT
    $OBIO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medicinal Chemicals and Botanical Products

    $OBIO
    Financials

    Live finance-specific insights

    View All

    Orchestra BioMed to Host Business Update Call on November 12, 2025

    NEW HOPE, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) ("Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced that company management will host a business update call on Wednesday, November 12th at 8:00 AM ET. The business update will focus on recent significant clinical, strategic and financing developments, including the Company's additional strategic investment from and collaboration expansion with Medtronic, its new strategic capital relationship with Ligand, its new right of first refusal agr

    11/3/25 8:00:00 AM ET
    $MDT
    $OBIO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medicinal Chemicals and Botanical Products

    Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients

    Hypertension is the most common comorbidity in the pacemaker population, affecting over 70% of patients or approximately 750,000 people annually worldwideMedtronic plc and Orchestra BioMed have an exclusive strategic collaboration for global development and commercialization of BackBeat Cardiac Neuromodulation Therapy™ (CNT), now also known as Atrioventricular Interval Modulation ("AVIM") therapy, for hypertensive pacemaker patientsBACKBEAT global pivotal study is expected to start before the end of 2023 IDE supported by data from the MODERATO II randomized pilot study that showed AVIM therapy drove significant and sustained reductions in blood pressure in hypertensive pacemaker patients Orc

    9/19/23 7:30:00 AM ET
    $MDT
    $OBIO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medicinal Chemicals and Botanical Products